Icahn School of Medicine at Mount Sinai
New York, 10128, United States
Location status: Recruiting
NCT Number: NCT05968573
A major impediment to emergency department (ED)-based HIV/HCV screening success is that often ED patients at risk for, or later diagnosed with, HIV and HCV decline testing. In this R01 project, the research team will assess how well a promising, easy-to-use, one-time, minimal-training-needed, very brief persuasive health communication intervention (PHCI) increases acceptance of testing among adult ED patients who either currently, formerly or never injected drugs and initially declined HIV/HCV screening. The research team will conduct a randomized, controlled trial (RCT) at EDs within the Mount Sinai Health System to compare the efficacy of the PHCI when delivered by a video vs. an HIV/HCV counselor. Patients who initially declined HIV/HCV screening will be stratified by injection-drug use (IDU) history cohorts: (1) current/former PWIDs, (2) never/non-PWIDs. Within each IDU history cohort, the research team will randomly assign participants (1:1:1) to a PHCI delivered by: (1) a video with captions, (2) a video without captions, (3) an HIV/HCV counselor. This R01 project will be conducted at Mount Sinai affiliate hospitals EDs. For Aim 2, the research team will determine if screening acceptance is similar across IDU history cohorts. For Aim 3, the research team will further compare the two delivery forms of the PHCI through a health economics assessment, both independent of IDU history and within each IDU history cohort.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
New York, 10128, United States
Location status: Recruiting
As part of routine practice at Mount Sinai Health System EDs, the ED Nurses initiate HIV/HCV screening for all patients able to provide consent. ED patients eligible for recruitment into the RCT portion of the study are those who declined HIV/HCV screening. RCs will review the electronic health records (EHRs) of patients present in the ED during data collection periods and determine which patients are potentially eligible.
Participation in the RCT involves a one-time encounter. All research-related activities will occur in the ED. As such, drop-out during this brief RCT (<30 minutes from recruitment through final study questionnaires) is expected to be minimal (<5%). RCs will coordinate with participants and ED staff to facilitate participant involvement while they are receiving medical care. If necessary, participants can continue participating in designated areas of the ED (e.g., waiting room, family room) after they are discharged and there are study-related tasks remaining. There are no research related follow-ups needed.
The research team will enroll a total of 2,000 adult ED patients who meet all study criteria and agree to participate in the RCT, stratified by IDU history. Assuming 0.6 participants completing the study/hour (1 study completion/75 minutes of recruitment, enrollment, and data collection), the research team could recruit up to ≈5,184 participants (720 collection days x 12 hours/data collection/day x 0.6 participants/hour) over 3 years.
The research team will be collecting data using the QDS™ (NOVA Research Company) program installed on a tablet computer. The program has the ability to encrypt collected data, to which only the researcher has ability to de-crypt data sets (NOVA Research cannot recover lost passwords for the researcher). The program also has a data management system, allowing data export for use in analytical packages like SPSS, Stata. Internet access is not necessary for this program to function. The data can be stored on the tablet computer for the meantime, then synced once internet is available.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
A video with captions created by the research team will be played to persuade patients to participate in HIV and Hepatitis C (HCV) screening.
A video without captions created by the research team will be played to persuade patients to participate in HIV and Hepatitis C (HCV) screening.
The video created by the research will be compared to a healthcare provider in terms of effectiveness in getting patients screened for HIV/HCV.
Time frame: Day 1, up to 5 minutes after intervention
The number of patients who accept HIV/HCV testing after watching the video with captions
Time frame: Day 1, up to 5 minutes after intervention
The number of patients who accept HIV/HCV testing after watching the video captions
Time frame: Day 1, up to 5 minutes after intervention
The number of patients who accept HIV/HCV testing after speaking with a health educator.
Time frame: Day 1, up to 5 minutes after intervention
The number of patients that accept HIV/HCV testing by no prior injection-drug use
Time frame: Day 1, up to 5 minutes after intervention
The number of patients that accept HIV/HCV testing by former injection-drug use
Time frame: Day 1, up to 5 minutes after intervention
The number of patients that accept HIV/HCV testing by current injection-drug use
Time frame: End of study, at 5 years
The research team will further compare the two delivery forms of the PHCI through a health economics assessment, both independent of IDU history and within each IDU history cohort. This will measure cost-benefit analysis in terms of cost of each intervention in relation to how effective it is on persuading real world populations to test for HIV and HCV.
Contact information is provided by the study sponsor or research team.
University of South Florida
Other
Evaluation of a Persuasive Health Communication Intervention Designed to Increase HIV/HCV Screening Among Emergency Departments Patients Who Currently, Formerly or Never Injected Drugs.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05657106
Acquired Immunodeficiency Syndrome, Blood-Borne Infections
Lexington, Kentucky, United States
View Trial DetailsNCT03290755
Acquired Immunodeficiency Syndrome, Behavior
Bordeaux, France
View Trial DetailsNCT07071623
Acquired Immunodeficiency Syndrome, Blood-Borne Infections
Homabay County, Homa Bay County, Kenya
View Trial DetailsNCT07044297
Acquired Immunodeficiency Syndrome, Blood-Borne Infections
Birmingham, Alabama, United States
View Trial Details